(The unfavorable trial had shown it was of little help to heart-attack patients. Its value has been proven for other patient populations.) On my trip to the Twin Cities a year ago, Possis Medical was one of my stops.Â I was impressed by how those who remained had great faith in the technology and were determined to see through a company turnaround. Now, with seven applications for new products or new uses for existing products pending before FDA -- and concern that drug-eluting stents may cause blood clots --Â Possis may be about to execute that turnaround. Kudos to Star Tribune reporter Janet Morse for taking note.